Bausch Health Companies Inc (BHC) – Strategic focus for long term growth

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Bausch Health Companies Inc (BHC) (Q4FY22)

Bausch Health is increasing investment in direct-to-consumer advertising, new sales force capabilities, and leveraging artificial intelligence and machine learning to accelerate the growth of XIFAXAN®

Bausch Health Companies reported revenues were $2.2bn for the fourth quarter of 2022, flat compared with the fourth quarter of 2021.

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value-Added Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10-Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s equity report click here

Follow our LinkedIn page for more updates